

Note: the clinical conditions included in this table are placed here as a way of separating the conditions into two tables and does not imply a formal definition of “joint health conditions”

HCU= Health care utilization

1. Rheumatoid arthritis flare domains: pain, function, swollen joints, tender joints, patient global, physician global, laboratory tests, fatigue, stiffness, participation, self-management (Bykerk 2014)
2. Note: Orbai 2016 is an update of the work by Gladman 2005 and Gladman 2007
3. Ankylosing spondylitis: Core domains vary depending on focus of study; domains that have to be measured in disease modification trials are an extension of the mandatory domains to be measured in symptom modification trials. <sup>4</sup>Mandatory in trials of disease modifying drugs.  
<sup>5</sup>For example, uveitis, inflammatory bowel disease, psoriasis  
<sup>6</sup>For example, arthritis, enthesitis, dactylitis
7. If impact of symptoms is specified, these would fall under Impact
8. Their assessment includes both swelling and pain
9. Mandatory in specific circumstances: hand mobility mandatory in clinical trials of structure modification and observational studies
10. Mandatory in specific circumstances: Juvenile Idiopathic Arthritis has domains that will be elicited if there are specific circumstances (i.e., eye involvement invokes assessment of uveitis). See reference for more complete list.
11. Radiographic damage measured in studies >1 year
12. Mandatory in specific circumstances: joint imaging mandatory in trials assessing interventions expected to change structure.
13. Acute phase proteins were named for systemic inflammation
14. Reporting of adverse events (including death) is mandatory in trials and death is a core area in OMERACT Filter 2.

## **References**

Wolfe 1999

Wolfe F, Lasserre M, van der Heijde D, et al.: Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology, *J Rheumatol* 1999. 26:484–489.

Boers 2014

Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d’Agostino MA, et al. Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. *J Clin Epidemiol* 2014; 67: 745-753

Boers 2018

Boers M, Beaton D, Shea B, Maxwell LJ, Bartlett S, Bingham III C, et al. OMERACT Filter 2.1: elaboration of the conceptual framework for outcome measurement in health intervention studies. *J Rheumatol*. 2019. 46(8):1021–1027

Boers, 1994

Boers M, Tugwell P, Felson DT, van Riel PLCM, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology Core Endpoints for Symptom Modifying Antirheumatic Drugs in Rheumatoid Arthritis Clinical Trials. *J Rheumatol* 1994;(suppl 41) 21:86-9

Felson, 1993;

Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B. et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum*. 1993 Jun;36:729-40.

Kirwan, 2007;

Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al. Patient Perspective: Fatigue as a Recommended Patient Centered Outcome Measure in Rheumatoid Arthritis. *J Rheumatol* 2007;34:1174–7

Bykerk 2014

Bykerk VP, Lie E, Bartlett SJ, Alten R, Boonen A, Christensen R, et al. Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop. *J Rheumatol* 2014; 41:799–809

Orbai, 2016

Orbai AM, de Wit M, Mease P, Callis Duffin K, Elmamoun M, Tillet W, et al. Updating the Psoriatic Arthritic Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. *J Rheumatol* 2017; 44:1522–1528

Schumacher, 2009

Schumacher HR, Taylor W, Edwards L, Grainger R, Schesinger N, Dalbeth N, et al. Outcome Domains for Studies of Acute and Chronic Gout. *J Rheumatol* 2009;36:2342–5

Smith, 2019

Smith TO, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, et al. The OMERACT-OARSI core domain set for measurement in clinical trials of hip and/or knee osteoarthritis. *J Rheumatol* 2019. Aug;46(8):981-989. doi: 10.3899/jrheum.181194

Kloppenborg, 2015

Kloppenborg M, Bøyesen P, Willemien Visser A, Haugen IK, Boers M, Boonen A, et al. Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. *J Rheumatol* 2015;42:2190-2197

Navarro-Compán 2021

Navarro-Compán, V., Boel, A. , Boonen, A, Mease, P., Landewé, R., Kiltz, U, et al. The ASAS-OMERACT core domain set for axial spondyloarthritis. *Seminars in arthritis and rheumatism*, 2021, Vol.51 (6), p.1342-1349. <https://doi.org/10.1016/j.semarthrit.2021.07.021>

Mackie, 2017

Mackie SL, Twohig H, Neill LM, Harrison E, Shea B, Black RJ, et al. The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. *J Rheumatol* 2017;44;1515-1521

Ramiro, 2019

Ramiro S, Page M, Whittle S, Huang H, Verhagen A, Beaton D, et al. The OMERACT core domain set for clinical trials of shoulder disorders. *J Rheumatol*. 2019;46:969–75; doi:10.3899/jrheum.181070

Morgan, 2019

Morgan E, Munro J, Horonjeff J, Shea B, Feldman B, Bingham III C, et al. Establishing an updated core domain set for studies in juvenile idiopathic arthritis: a report from the OMERACT 2018 JIA Workshop. *J Rheumatol*. 2019 Aug;46(8):1006-1013. doi: 10.3899/jrheum.181088